Role of Class II nuclear receptors in liver carcinogenesis.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Anti-Cancer Agents in Medicinal Chemistry

• Publication date

  2011-06-30

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.2174/187152011796011064PMID 21554208
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Steroid hormone receptors in cancer development: a target for cancer therapeutics.

  2011cited by this paper
• PPARs as therapeutic targets in cardiovascular disease

  2010cited by this paper
• Bile acids and their nuclear receptor FXR: Relevance for hepatobiliary and gastrointestinal disease.

  2010cited by this paper
• Molecular approaches to treatment of hepatocellular carcinoma.

  2010cited by this paper
• Epidemiology of Hepatocellular Carcinoma

  2010cited by this paper
• Estrogen-dependent gallbladder carcinogenesis in LXRβ−/− female mice

  2010cited by this paper
• Hepatocellular carcinoma: a global view

  2010cited by this paper
• Nuclear receptors, inflammation, and neurodegenerative diseases.

  2010cited by this paper
• Pathogenesis of alcoholic liver disease: the role of nuclear receptors

  2010cited by this paper
• A Conserved Lysine in the Thyroid Hormone Receptor–α1 DNA-Binding Domain, Mutated in Hepatocellular Carcinoma, Serves as a Sensor for Transcriptional Regulation

  2010cited by this paper
• Non-viral causes of hepatocellular carcinoma.

  2010cited by this paper
• Cancer gene discovery in hepatocellular carcinoma.

  2010cited by this paper
• Nuclear receptors as drug targets in cholestasis and drug-induced hepatotoxicity.

  2010cited by this paper
• Genome‐wide tissue‐specific farnesoid X receptor binding in mouse liver and intestine

  2010cited by this paper
• Current status of molecularly targeted therapy for hepatocellular carcinoma: basic science

  2010cited by this paper
• Non-alcoholic fatty liver disease as a risk factor for hepatocellular carcinoma: mechanisms and implications

  2010cited by this paper
• Radiofrequency ablation in the treatment of small hepatocellular carcinoma: a meta analysis.

  2010cited by this paper
• Enhanced steatosis by nuclear receptor ligands: a study in cultured human hepatocytes and hepatoma cells with a characterized nuclear receptor expression profile.

  2010cited by this paper
• Oncogenic potential of retinoic acid receptor-gamma in hepatocellular carcinoma.

  2010cited by this paper
• Current approaches to the treatment of early hepatocellular carcinoma.

  2010cited by this paper
• Thyroid hormone receptor-mediated regulation of the methionine adenosyltransferase 1 gene is associated with cell invasion in hepatoma cell lines

  2010cited by this paper
• Role of vitamin D in cardiovascular disease.

  2010cited by this paper
• Comparison of gene expression in hepatocellular carcinoma, liver development, and liver regeneration

  2010cited by this paper
• Issues and updates: evaluating estrogen receptor-α, progesterone receptor, and HER2 in breast cancer

  2010cited by this paper
• Radiofrequency Ablation for Hepatocellular Carcinoma: Updated Review in 2010

  2010cited by this paper
• Liver X receptor in cholesterol metabolism.

  2010cited by this paper
• Tumor initiation and progression in hepatocellular carcinoma: risk factors, classification, and therapeutic targets

  2010cited by this paper
• From chronic liver disorders to hepatocellular carcinoma: Molecular and genetic pathways.

  2010cited by this paper
• PPARalpha: an emerging therapeutic target in diabetic microvascular damage.

  2010cited by this paper
• The role of signaling pathways in the development and treatment of hepatocellular carcinoma

  2010cited by this paper
• Negative regulation of the oncogenic transcription factor FoxM1 by thiazolidinediones and mithramycin

  2010cited by this paper
• Structural overview of the nuclear receptor superfamily: insights into physiology and therapeutics.

  2010cited by this paper
• Hepatitis B virus X protein overcomes the growth-inhibitory potential of retinoic acid by downregulating retinoic acid receptor-beta2 expression via DNA methylation.

  2010cited by this paper
• Vitamin D receptor gene polymorphisms and hepatocellular carcinoma in alcoholic cirrhosis.

  2010cited by this paper
• Human constitutive androstane receptor (CAR) and pregnane X receptor (PXR) support the hypertrophic but not the hyperplastic response to the murine nongenotoxic hepatocarcinogens phenobarbital and chlordane in vivo.

  2010cited by this paper
• Inhibitory role of peroxisome proliferator‐activated receptor gamma in hepatocarcinogenesis in mice and in vitro

  2010cited by this paper
• Transarterial chemoembolization (TACE) for unresectable HCC: a new life begins?

  2010cited by this paper
• The nuclear receptor PXR gene variants are associated with liver injury in nonalcoholic fatty liver disease

  2010cited by this paper
• Current approach in the treatment of hepatocellular carcinoma.

  2010cited by this paper
• Peroxisome proliferator-activated receptor beta/delta (PPARbeta/delta) acts as regulator of metabolism linked to multiple cellular functions.

  2010cited by this paper
• Molecularly targeted therapy in hepatocellular carcinoma.

  2010cited by this paper
• Nuclear receptor regulation of the adaptive response of bile acid transporters in cholestasis.

  2010cited by this paper
• The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective.

  2010cited by this paper
• Cytosolic phospholipase A2α and peroxisome proliferator‐activated receptor γ signaling pathway counteracts transforming growth factor β–mediated inhibition of primary and transformed hepatocyte growth

  2010cited by this paper
• The role of microRNAs in liver cancer progression

  2010cited by this paper
• Microarray-Based Gene Expression Analysis of Hepatocellular Carcinoma

  2010cited by this paper
• The nuclear receptor superfamily of steroid hormones and vitamin D gene regulation

  2010cited by this paper
• Thiazolidinediones inhibit hepatocarcinogenesis in hepatitis B virus–transgenic mice by peroxisome proliferator‐activated receptor γ–independent regulation of nucleophosmin

  2010cited by this paper
• Thyroid hormone receptor beta1 acts as a potent suppressor of tumor invasiveness and metastasis.

  2009cited by this paper
• Rosiglitazone sensitizes hepatocellular carcinoma cell lines to 5-fluorouracil antitumor activity through activation of the PPARγ signaling pathway

  2009cited by this paper
• The constitutive active/androstane receptor facilitates unique phenobarbital-induced expression changes of genes involved in key pathways in precancerous liver and liver tumors.

  2009cited by this paper
• Peroxisome proliferator-activated receptor delta and gastric cancer (Review).

  2009cited by this paper
• Multiple genes exhibit phenobarbital-induced constitutive active/androstane receptor-mediated DNA methylation changes during liver tumorigenesis and in liver tumors.

  2009cited by this paper
• Meta-analysis of percutaneous radiofrequency ablation versus ethanol injection in hepatocellular carcinoma

  2009cited by this paper
• The aryl hydrocarbon receptor in immunity.

  2009cited by this paper
• Sorting out the functional role(s) of peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) in cell proliferation and cancer.

  2009cited by this paper
• PXR and CAR in energy metabolism.

  2009cited by this paper
• Thyroid hormone receptor ligands induce regression of rat preneoplastic liver lesions causing their reversion to a differentiated phenotype

  2009cited by this paper
• Emerging roles of peroxisome proliferator-activated receptor-beta/delta in inflammation.

  2009cited by this paper
• Cytoplasmic alpha-fetoprotein functions as a co-repressor in RA-RAR signaling to promote the growth of human hepatoma Bel 7402 cells.

  2009cited by this paper
• Trim24 targets endogenous p53 for degradation

  2009cited by this paper
• Human health risk assessment for peroxisome proliferators: more than 30 years of research.

  2009cited by this paper
• Peroxisome proliferator-activated receptor alpha plays a crucial role in L-carnitine anti-apoptosis effect in renal tubular cells.

  2009cited by this paper
• The peroxisome proliferator-activated receptor gamma ligands, pioglitazone and 15-deoxy-Delta(12,14)-prostaglandin J(2), have antineoplastic effects against hepatitis B virus-associated hepatocellular carcinoma cells.

  2009cited by this paper
• Farnesoid X receptor agonists in biliary tract disease

  2009cited by this paper
• Pathogenesis of hepatocellular carcinoma and molecular therapies

  2009cited by this paper
• Review article: nuclear receptors and liver disease – current understanding and new therapeutic implications

  2009cited by this paper
• Bile acids and insulin resistance: implications for treating nonalcoholic fatty liver disease

  2009cited by this paper
• Thiazolidinediones in prediabetes and early type 2 diabetes: What can be learned about that disease’s pathogenesis

  2009cited by this paper
• Liver X receptor mediates hepatitis B virus X protein–induced lipogenesis in hepatitis B virus–associated hepatocellular carcinoma

  2009cited by this paper
• Nuclear receptors CAR and PXR: Molecular, functional, and biomedical aspects.

  2009cited by this paper
• Thyroid hormone receptor (TR) mutants implicated in human hepatocellular carcinoma display an altered target gene repertoire

  2009cited by this paper
• Apoptosis induced in HepG2 cells by the synthetic cannabinoid WIN: involvement of the transcription factor PPARgamma.

  2009cited by this paper
• Vitamin D gene pathway polymorphisms and risk of colorectal, breast, and prostate cancer.

  2009cited by this paper
• Peroxisome Proliferator-Activated Receptor γ Pathway Targeting in Carcinogenesis: Implications for Chemoprevention

  2009cited by this paper
• PXR: a xenobiotic receptor of diverse function implicated in pharmacogenetics.

  2008cited by this paper
• Overexpression of Jab1 in Hepatocellular Carcinoma and Its Inhibition by Peroxisome Proliferator-Activated Receptorγ Ligands In vitro and In vivo

  2008cited by this paper
• Peroxisome proliferator-activated receptor-beta/delta protects against chemically induced liver toxicity in mice.

  2008cited by this paper
• Molecular targeted therapies in hepatocellular carcinoma

  2008cited by this paper
• Ligand activation of peroxisome proliferator-activated receptor beta/delta (PPARbeta/delta) attenuates carbon tetrachloride hepatotoxicity by downregulating proinflammatory gene expression.

  2008cited by this paper
• Mechanisms of anti-inflammatory and neuroprotective actions of PPAR-gamma agonists.

  2008cited by this paper
• Farnesoid X receptor antagonizes nuclear factor κB in hepatic inflammatory response

  2008cited by this paper
• Trim24 (Tif1 alpha): an essential 'brake' for retinoic acid-induced transcription to prevent liver cancer.

  2008cited by this paper
• Role of peroxisome-proliferator-activated receptor beta/delta (PPARbeta/delta) in gastrointestinal tract function and disease.

  2008cited by this paper
• Pioglitazone, a ligand for peroxisome proliferator-activated receptor-gamma acts as an inhibitor of colon cancer liver metastasis.

  2008cited by this paper
• Structure and physiological functions of the human peroxisome proliferator-activated receptor γ

  2008cited by this paper
• Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis.

  2008cited by this paper
• FXR signaling in metabolic disease

  2008cited by this paper
• Fat and beyond: the diverse biology of PPARgamma.

  2008cited by this paper
• Molecular mechanisms of hepatocellular carcinoma

  2008cited by this paper
• C‐Myc and its target FoxM1 are critical downstream effectors of constitutive androstane receptor (CAR) mediated direct liver hyperplasia

  2008cited by this paper
• FXR: a metabolic regulator and cell protector

  2008cited by this paper
• Hepatic fatty acid transporter Cd36 is a common target of LXR, PXR, and PPARgamma in promoting steatosis.

  2008cited by this paper
• Cancer Statistics, 2008

  2008cited by this paper
• Peroxisome proliferator‐activated receptor‐δ induces insulin‐induced gene‐1 and suppresses hepatic lipogenesis in obese diabetic mice

  2008cited by this paper
• Genomics and signaling pathways in hepatocellular carcinoma.

  2007cited by this paper
• A peroxisome proliferator-activated receptor gamma antagonist induces vimentin cleavage and inhibits invasion in high-grade hepatocellular carcinoma.

  2007cited by this paper
• Spontaneous development of liver tumors in the absence of the bile acid receptor farnesoid X receptor.

  2007cited by this paper
• Loss of Trim24 (Tif1α) gene function confers oncogenic activity to retinoic acid receptor alpha

  2007cited by this paper
• Regulation of the human cathepsin E gene by the constitutive androstane receptor.

  2007cited by this paper

• The protective effects of sesamol and/or the probiotic, Lactobacillus rhamnosus, against aluminum chloride-induced neurotoxicity and hepatotoxicity in rats: Modulation of Wnt/β-catenin/GSK-3β, JAK-2/STAT-3, PPAR-γ, inflammatory, and apoptotic pathways

  2023cites this paper
• From NASH to HCC: current concepts and future challenges

  2019cites this paper
• Xenobiotic Receptor-Mediated Carcinogenesis

  2018cites this paper
• Microtargeting cancer metabolism: opening new therapeutic windows based on lipid metabolism

  2016cites this paper
• Microtargeting cancer metabolism: opening new therapeutic windows based on lipid metabolism.

  2016cites this paper
• Farnesoid X receptor, the bile acid sensing nuclear receptor, in liver regeneration

  2015cites this paper
• Small heterodimer partner overexpression partially protects against liver tumor development in farnesoid X receptor knockout mice.

  2013cites this paper
• PPARs Signaling and Cancer in the Gastrointestinal System

  2012influential citation
• PPARs in Liver Diseases and Cancer: Epigenetic Regulation by MicroRNAs

  2012cites this paper